An observational study in Acute Cardiovascular Disease, Acute Coronary Syndrome and Acute Heart Failure, sponsored by Federico II University. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-03.
Sponsored by Federico II University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Acute Coronary Syndrome by Federico II University — 3 open to participants now, 4 under way, none of them phase 3. Acute Coronary Syndrome · Federico II University.
Among the 10 studies in Acute Coronary Syndrome by Federico II University, this one is the only one that started in 2023, is one of 6 observational ones, and was the 10th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →3 of the 10 studies in Acute Coronary Syndrome by Federico II University are open now, in 1 country. Recruiting first, the newest first:
Federico II University · Sites in Italy
Ages 18+
Federico II University · Sites in Italy
Ages 18+
By country, each count listing its studies:
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.
Median enrollment 80 across the 4 interventional studies, 2,750 across the 6 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Federico II University is the lead sponsor of 366 studies on the registry; 60 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Acute Coronary Syndrome by Federico II University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This protocol proposes to prospectively evaluate current epidemiology, pharmacologic and invasive management and clinical outcomes of patients with acute cardiovascular diseases admitted at our ICCU.
This study is designed as a single-center, investigator-initiated prospective observational study. Our ICCU is located at the Department of "Scienze Cardiovascolari, Diagnostica per Immagini, e Rete Tempo Dipendente delle Emergenze Cardiovascolari" of the Azienda Ospedaliera Universitaria Federico II. All scientific activities are performed in the Department of Advanced Biomedical Sciences of the University of Naples Federico II.
This is a prospective observational study which does not include pharmacologic or invasive treatments different from daily and guideline-directed management, but only collects data of patients for research purposes, therefore no specific treatments or procedures are included in this research protocol.
The Clinical Trial Unit at the University of Naples "Federico II" will oversee all study procedures and data management. The study data will be anonymized and managed using REDCap electronic data capture, which is hosted at the University of Naples "Federico II".
Once the patient is admitted to our ICCU, the informed consent will be signed and all data will be collected: demographic, clinical, procedural, therapeutic, and outcome data.
Clinical outcomes will be assessed in the in-hospital period, at 30 days, at 1-year and at the longest available follow-up (telephone or follow-up visit).
Main clinical outcomes will be adjudicated by an independent clinical events committee (CEC).
All adult patients with acute cardiovascular diseases admitted at our ICCU will be eligible for inclusion in the study, and only those not providing consent to data collection will be excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All-cause mortality
Number of patients with all-cause mortality
Time frame: 30 days, 1 year
Cardiovascular mortality
Number of patients with cardiovascular mortality
Time frame: 30 days, 1 year
Myocardial infarction
Number of patients with myocardial infarction
Time frame: 30 days, 1 year
Stent thrombosis
Number of patients with stent thrombosis
Time frame: 30 days, 1 year
Stroke
Number of patients with stroke
Time frame: 30 days, 1 year
Heart Failure
Number of patients with heart failure
Time frame: 30 days, 1 year
Hospitalization for heart failure
Number of patients with hospitalization for heart failure
Time frame: 30 days, 1 year
Bleeding
Number of patients with bleeding
Time frame: 30 days, 1 year
Acute kidney injury
Number of patients with acute kidney injury
Time frame: 30 days, 1 year
Target vessel revascularization
Number of patients with target vessel revascularization
Time frame: 30 days, 1 year
Target lesion revascularization
Number of patients with target lesion revascularization
Time frame: 30 days, 1 year
Hospital length of stay
Duration of hospitalization in days
Time frame: 0 to 30 days (or more depending on diration of hospitalization)
Metrics of diuretic response and decongestion
Diuresis quantification, weight loss, decongestion score, etc.
Time frame: 0 to 30 days (or more depending on diration of hospitalization)
Poor neurologic outcomes
Number of patients with poor neurologic outcomes
Time frame: 30 days, 1 year
ICCU length of stay
Duration of ICCU hospitalization in days
Time frame: 0 to 30 days (or more depending on diration of hospitalization)
Metrics of need for mechanical circulatory support and vasopressors/inotropes
Need for MCS, MCS type and duration; need for vasopressors/inotropes, vasopressors/inotropes types and duration
Time frame: 0 to 30 days (or more depending on diration of hospitalization)
Quality of life
Quality of life assessment by various scores or questionnaires
Time frame: 30 days, 1 year
Plan to share: No
Started Nov 2023 (actual). Primary completion is estimated for Nov 2033, 120 months after the start.
Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 120 months is above that.
Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.